Propranolol

Generic Name: Propranolol

Brand Names: Hemangeol, Hemangiol, Inderal, Innopran

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁NO_₂

CAS Number: 525-66-6

Unique Ingredient Identifier: 9Y8NXQ24VQ

Background: Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.

Propranolol was granted FDA approval on 13 November 1967.

Indication: Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.

Associated Conditions: Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)

Associated Therapies: -

Clinical Trials

PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation

Phase 4

Terminated

Conditions: Posttraumatic Stress Disorders

Interventions: Drug: Placebo
Drug: Propranolol

First Posted Date: 2008-03-27

Last Posted Date: 2019-07-02

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 9

Registration Number: NCT00645450

Locations: 🇺🇸
VA Medical Center, Manchester, Manchester, New Hampshire, United States

The Use of Propranolol to Block Memory Reconsolidation in PTSD

Phase 2

Terminated

Conditions: Posttraumatic Stress Disorders

Interventions: Drug: Placebo
Drug: Propranolol

First Posted Date: 2008-02-11

Last Posted Date: 2016-11-01

Lead Sponsor: Wayne State University

Target Recruit Count: 12

Registration Number: NCT00611871

Locations: 🇺🇸
John D Dingell VA Hospital, Detroit, Michigan, United States

Optimising the Propranolol Block Model

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Propranolol
Drug: Salbutamol
Drug: Placebo
Drug: Ipratropium

First Posted Date: 2007-10-25

Last Posted Date: 2017-08-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT00549120

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Danish Carvedilol Study in Portal Hypertension

Phase 3

Completed

Conditions: Cirrhosis
Portal Hypertension

Interventions: Drug: carvedilol
Drug: propranolol

First Posted Date: 2007-06-28

Last Posted Date: 2009-08-10

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 40

Registration Number: NCT00493480

Locations: 🇩🇰
Hvidovre Hospital, Hvidovre, Denmark

Propranolol in Post Traumatic Stress Disorder

Phase 2

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: propranolol

First Posted Date: 2007-04-25

Last Posted Date: 2009-01-07

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 20

Registration Number: NCT00465608

Locations: 🇫🇷
Psychiatric Department, Toulouse, France

Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions

Phase 2

Completed

Conditions: Regional Blood Flow
Ocular Physiology

First Posted Date: 2007-02-05

Last Posted Date: 2007-02-05

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 42

Registration Number: NCT00431392

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia

Phase 3

Completed

Conditions: Supraventricular Tachycardia

Interventions: Drug: Propranolol
Drug: Digoxin

First Posted Date: 2006-10-20

Last Posted Date: 2017-12-13

Lead Sponsor: University of British Columbia

Target Recruit Count: 72

Registration Number: NCT00390546

Locations: 🇨🇦
Hospital for Sick Kids, Toronto, Ontario, Canada
🇺🇸
University of Southern California - Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
The Children's Mercy Hospital, Kansas City, Missouri, United States

and more 11 locations

Beta Blockade in Critical Injury

Phase 2

Terminated

Conditions: Trauma

Interventions: Drug: Propranolol

First Posted Date: 2006-07-25

Last Posted Date: 2018-03-15

Lead Sponsor: Denver Health and Hospital Authority

Target Recruit Count: 15

Registration Number: NCT00356187

Locations: 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States

Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding

Phase 3

Terminated

Conditions: Liver Cirrhosis
Esophageal Varices

First Posted Date: 2006-06-16

Last Posted Date: 2012-04-23

Lead Sponsor: University of Padova

Target Recruit Count: 120

Registration Number: NCT00337740

Locations: 🇮🇹
Clinica Chirurgica 1^, Policlinico Universitario, Via Giustiniani 2, Padova, Italy

Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis

Phase 4

Conditions: Liver Cirrhosis
Portal Hypertension

Interventions: Drug: propranolol
Drug: spironolactone

First Posted Date: 2006-06-02

Last Posted Date: 2010-06-04

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 22

Registration Number: NCT00332904

Locations: 🇩🇰
Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital, Hvidovre, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy